Kromek Group (LON:KMK) Full Year 2025 Results
Key Financial Results
- Revenue: UK£26.5m (up 37% from FY 2024).
- Net income: UK£3.75m (up from UK£3.29m loss in FY 2024).
- Profit margin: 14% (up from net loss in FY 2024).
- EPS: UK£0.006 (up from UK£0.006 loss in FY 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Kromek Group EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.4%.
Looking ahead, revenue is forecast to grow 7.1% p.a. on average during the next 2 years, compared to a 8.3% growth forecast for the Semiconductor industry in Europe.
Performance of the market in the United Kingdom.
The company's shares are up 12% from a week ago.
Risk Analysis
Be aware that Kromek Group is showing 2 warning signs in our investment analysis and 1 of those is potentially serious...
Valuation is complex, but we're here to simplify it.
Discover if Kromek Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:KMK
Kromek Group
Develops, manufactures, and sells radiation detection components and devices for the advanced imaging, CBRN detection, and biological threat detection markets.
Excellent balance sheet with acceptable track record.
Market Insights
Community Narratives


